The treatment of malaria, the most common parasitic disease worldwide and the third deadliest infection after HIV and tuberculosis, is nowadays harmed by the dramatic increase and diffusion of drug-resistance among the different species of Plasmodium, especially P. falciparum (Pf). In this view, the development of new antiplasmodial agents, able to act via innovative mechanisms of action, is crucial to ensure efficacious antimalarial treatments. In one of our previous communications, we described a novel class of compounds endowed with high antiplasmodial activity, characterized by a pharmacophore never described before as antiplasmodial and identified in their 4,4'-oxybisbenzoyl amide cores. Here, through a detailed structure-activity relationship (SAR) study, we deeply investigated the chemical features of the reported scaffolds and successfully built a novel antiplasmodial agent active on both chloroquine (CQ) sensitive and CQ-resistant Pf strains in the low nanomolar range, without displaying cross resistance. Moreover, we conducted an in silico pharmacophore mapping.
Discovery and pharmacophore mapping of a new low nanomolar inhibitor of P. falciparum growth / I. Bassanini, S. Parapini, C. Galli, N. Vaiana, A. Pancotti, N. Basilico, D. Taramelli, S. Romeo. - In: CHEMMEDCHEM. - ISSN 1860-7179. - (2019). [Epub ahead of print] [10.1002/cmdc.201900526]
Discovery and pharmacophore mapping of a new low nanomolar inhibitor of P. falciparum growth
I. BassaniniPrimo
;S. ParapiniSecondo
;C. Galli;N. Vaiana;A. Pancotti;N. Basilico;D. TaramelliPenultimo
;S. Romeo
Ultimo
2019
Abstract
The treatment of malaria, the most common parasitic disease worldwide and the third deadliest infection after HIV and tuberculosis, is nowadays harmed by the dramatic increase and diffusion of drug-resistance among the different species of Plasmodium, especially P. falciparum (Pf). In this view, the development of new antiplasmodial agents, able to act via innovative mechanisms of action, is crucial to ensure efficacious antimalarial treatments. In one of our previous communications, we described a novel class of compounds endowed with high antiplasmodial activity, characterized by a pharmacophore never described before as antiplasmodial and identified in their 4,4'-oxybisbenzoyl amide cores. Here, through a detailed structure-activity relationship (SAR) study, we deeply investigated the chemical features of the reported scaffolds and successfully built a novel antiplasmodial agent active on both chloroquine (CQ) sensitive and CQ-resistant Pf strains in the low nanomolar range, without displaying cross resistance. Moreover, we conducted an in silico pharmacophore mapping.File | Dimensione | Formato | |
---|---|---|---|
document(3).pdf
Open Access dal 01/01/2021
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
1.82 MB
Formato
Adobe PDF
|
1.82 MB | Adobe PDF | Visualizza/Apri |
cmdc.201900526.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.07 MB
Formato
Adobe PDF
|
2.07 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.